Supplements for post-COVID recovery
An evidence-graded supplement guide for the weeks and months after acute COVID — for ordinary recovery, not as a substitute for long-COVID specialist care.
The post-COVID stack — practical and layered
Foundation (weeks 1–4)
Vitamin D3 to a 25-OH-D target of 30–50 ng/mL (2,000–4,000 IU/day if deficient). Omega-3 EPA+DHA 1–2 g/day. Magnesium bisglycinate 200–400 mg elemental in the evening for sleep and recovery. Zinc 15–30 mg/day during acute symptoms; stop within 4 weeks (chronic high zinc lowers copper).
Get bloodwork at week 4–6 if symptoms persist
CBC, ferritin, 25-OH-D, B12 with methylmalonic acid, TSH, ALT, fasting glucose. Low ferritin (<50 ng/mL) is common after acute infection and worsens fatigue. Low B12 is common in vegetarian/PPI users and presents similarly to long-COVID symptoms. Address deficiencies in target-driven fashion rather than blanket-dosing every nutrient.
Sleep, fatigue, and exercise pacing
Graded reintroduction of exercise — recumbent first if exertional symptoms (palpitations, post-exertional malaise) are present; this matches the Levine POTS protocol. Pushing too hard too soon worsens post-exertional symptoms in users developing long COVID. Sleep hygiene fundamentals.
If symptoms persist beyond 12 weeks — escalate
Persistent fatigue, breathlessness, cognitive symptoms ("brain fog"), or autonomic symptoms (postural tachycardia, dizziness) beyond 12 weeks meet provisional long-COVID criteria. See a long-COVID clinic if available. The supplement layer at this point is genuinely adjunctive to specialist care that includes graded exercise, cognitive rehabilitation, and pharmacological options for specific syndromes (POTS, MCAS, dysautonomia).
NAC and antioxidants
NAC at 600 mg b.i.d. has small mechanism-based rationale (glutathione repletion during post-infectious oxidative stress) and is generally well-tolerated. Effect sizes in published post-COVID trials are modest. Reasonable 4–8 week trial; stop if no perceived benefit.
Gut recovery after antibiotic course (if applicable)
If antibiotics were used during acute illness: Lactobacillus rhamnosus GG or Saccharomyces boulardii ≥10 billion CFU/day for 2 weeks after antibiotic completion. Otherwise skip the broad-spectrum probiotic.
What to skip
- 30-ingredient "long COVID protocols" — diluted ingredients, no rigorous trial data; marketing-led rather than evidence-led.
- Ivermectin, hydroxychloroquine, fluvoxamine "preventive" or "recovery" use — outside trial protocols, these have not shown benefit in well-conducted post-COVID studies.
- High-dose vitamin C (5+ g/day chronic) — no recovery-phase benefit; GI side effects.
- Mega-dose vitamin D bolus (50,000 IU+ single doses) — pharmacokinetics favour daily/weekly dosing for status; mega-bolus has paradoxical risk signals.
- "Spike protein detox" stacks with nattokinase + bromelain + cocktail of others — no controlled trial evidence for these as a category.
- Chronic high-dose zinc (>30 mg/day beyond 4 weeks) — copper deficiency develops with chronic high zinc.
- Stimulant nootropics or pre-workouts pushed by "energy" marketing — wrong target for post-viral fatigue and can worsen autonomic symptoms.
- Pushing through exertional symptoms with caffeine — not a supplement issue exactly, but the most common self-management error during post-COVID recovery.
Sources
- Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146. PMID: 36639608
- Adams JM, et al. Vitamin D and COVID-19: an update. Adv Nutr. 2022;13(5):1684–1693. PMID: 35421229
- Calder PC. Nutrition, immunity and COVID-19. BMJ Nutr Prev Health. 2020;3(1):74–92. PMID: 33230497
- Stoffel NU, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days. Lancet Haematol. 2017;4(11):e524–e533. PMID: 29032957
- Trasino SE. A role for retinoids in the treatment of COVID-19? Clin Exp Pharmacol Physiol. 2020;47(10):1765–1767. PMID: 32459003
- Hultström M, et al. Reduced micronutrient status of intensive care patients with COVID-19. Crit Care. 2022;26(1):116. PMID: 35468867